Kenya’s Pharmacy and Poisons Board has sounded a national alarm over the rapidly spreading use of Ozempic — a prescription drug approved strictly for managing Type 2 diabetes — after counterfeit versions of the injectable pen were found circulating in Nairobi and other urban centres. The regulator’s warning, issued amid a sharp surge of influencer-driven marketing and informal wellness sales across the country, signals a deepening public health concern as urban Kenyans spend tens of thousands of shillings monthly on unverified cosmetic weight-loss treatments.
Ozempic, whose active ingredient is semaglutide, was developed and licensed specifically to help control blood sugar levels in adults living with Type 2 diabetes. Its notable side effect of appetite suppression and significant weight reduction has, however, made it a global phenomenon among those seeking rapid body transformation without lasting lifestyle changes. In Kenya, social media influencers and informal wellness vendors have aggressively marketed the injections as an accessible shortcut, with some Nairobi users reportedly spending between KSh 50,000 and KSh 100,000 per month on the drug — a figure that places it firmly in the luxury bracket for most Kenyan households and raises stark questions about equity in healthcare access.
The more alarming dimension of Kenya’s Ozempic crisis is the proliferation of counterfeit pens flooding the informal market. The Pharmacy and Poisons Board has confirmed that fake versions of the drug — some containing harmful or unidentified substances, others simply inactive fillers — have been found in active circulation. Unlike pharmaceutical-grade semaglutide, which requires strict cold-chain storage and must be administered under professional medical supervision, these counterfeit products carry none of those safeguards. Consumers purchasing Ozempic through unregulated social media vendors, informal markets or unlicensed clinics face real and serious risks, ranging from dangerous adverse reactions to complete treatment failure.
The Ozempic trend in Kenya reflects a wider pattern seen across middle-income countries where global appetite for celebrity-endorsed weight-loss solutions collides with limited regulatory enforcement and rapid social media adoption. Kenya’s wellness and beauty industry has expanded sharply in recent years, with influencers commanding significant sway over consumer health choices, particularly among younger urban demographics. The Pharmacy and Poisons Board has responded by initiating a formal crackdown on both influencers and clinics promoting Ozempic outside its approved medical indication, warning that promoters and unlicensed practitioners could face legal consequences under Kenyan pharmaceutical law.
The episode raises pressing questions about the intersection of social media influence, consumer healthcare access and pharmaceutical oversight in Kenya. Medical professionals have strongly urged anyone considering weight-management medication to consult a licensed physician rather than follow influencer endorsements or purchase from informal vendors. The Pharmacy and Poisons Board is calling on Kenyans to report suspected counterfeit pharmaceuticals directly to its offices and to obtain prescription drugs only through licensed pharmacies and hospitals. The Ozempic warning stands as a broader caution that prescription medicines carry serious, sometimes life-threatening risks when used without qualified medical guidance — a reminder that is especially urgent in a market where counterfeit drugs remain a persistent and poorly monitored challenge.
0 comments